Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients.

ABSTRACT: Vaccination is the primary public health strategy to cope with the COVID-19 pandemic. Although solid tumor and hematologic patients are at higher risk of serious COVID-19-related complications, data on immune responses to COVID-19 vaccines in this patient cohort are particularly scarce. The present study, therefore, aimed at the standardized determination of anti-SARS-CoV-2 spike protein antibody titers among non-vaccinated versus vaccinated solid tumor and hematologic patients who are under clinical observation or under treatment at the University Hospital Krems. Standardized anti-SARS-CoV-2 S antibody titers of a total of 441 patients were retrospectively analyzed. Our results show that antibody titers against the SARS-CoV-2 spike protein are significantly higher in solid tumor versus he

SUBMITTER: Singer J 

PROVIDER: S-EPMC8430869 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature